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Background: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by B-cell hyper-
reactivity and the production of pathogenic anti-nuclear-directed auto-antibodies (Abs). B-cell ontogeny is partly
dependent on the CXCL12/CXCR4 axis for which the contribution to SLE pathogenesis remains unclear. CXCR7, the
novel receptor for CXCL12, is differentially expressed among memory B-cell subsets. However, its biological role in
SLE remains to be explored.
Methods: Relative CXCR4 and CXCR7 expression levels were compared by quantitative PCR in leukocytes from
blood samples of 41 Mexican Mestizos patients with SLE and 45 ethnicity-matched healthy subjects. Intracellular
and membrane expression of both receptors was analyzed by flow cytometry in naive and Ab-secreting B cells.
B-cell responsiveness to CXCL12 was investigated using Transwell-based chemotaxis assays. Data were analyzed
using the Kruskal-Wallis test for comparisons of values amongst healthy controls and patients with inactive or active
SLE, and non-parametrically using the Mann–Whitney U-test for multiple comparisons and unpaired samples.
Correlations were determined by Spearman’s ranking.
Result: SLE leukocytes displayed reduced levels of CXCR4 and CXCR7 transcripts. In SLE patients, a significant defect
in CXCR4 expression was detected at the surface of naive and Ab-secreting B cells, associated with an abnormal
intracellular localization of the receptor. CXCR7 predominantly localized in cytosolic compartments of B cells from
healthy and SLE individuals. Disease activity did not impact on these expression patterns. Altered receptor
compartmentalization correlated with an impaired CXCL12-promoted migration of SLE B cells.
Conclusions: Our data highlight a down-regulation of CXCL12 receptors on circulating B cells from SLE patients
that likely influences their migratory behavior and distribution.
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Systemic Lupus Erythematosus (SLE) is a prototypical
chronic and systemic autoimmune disease with hetero-
geneous clinical manifestations and various immune dys-
functions [1]. Genetic factors play an important role in* Correspondence: karl.balabanian@u-psud.fr
†Equal contributors
ˆDeceased
1Université Paris-Sud, Laboratoire "Cytokines, Chimiokines et Immunopathologie",
UMR_S996, Clamart, France
2INSERM, Laboratory of Excellence in Research on Medication and Innovative
Therapeutics (LERMIT), Clamart, France
Full list of author information is available at the end of the article
© 2012 Biajoux et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthe susceptibility to SLE development [2]. Such complex
disease affects multiple organs and results in death par-
ticularly when kidney damage is severe. SLE is notably
characterized by a strong humoral response. A wide array
of intrinsic B-cell defects, including B-cell hyper-reactivity
and the production of auto-antibodies (Abs) against
dsDNA and ribonucleoproteins, has been documented in
SLE patients [3,4]. These pathogenic anti-nuclear Abs are
thought to agglomerate and form immune complexes,
thus leading to organ destruction [5]. Perturbations of per-
ipheral B-cell homeostasis (e.g. increased CD27high plasma
cells [PC]), deposition of immune complexes andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion of B cells to SLE pathogenesis [6-8]. Hence, B-cell
targeted therapies such as rituximab and epratuzumab,
two humanized monoclonal Abs (mAbs) directed against
surface molecules CD20 and CD22 respectively, are of
interest for improving current treatments mostly based on
non-specific immunosuppressive drugs [7,9].
Chemokines are small cytokine-like secreted proteins
that govern migration of leukocytes to specific niches in
lymphoid organs and inflammatory sites. They mediate
their functions by binding and activating chemokine recep-
tors, which belong to the seven-transmembrane G protein-
coupled receptor family [10]. The chemokine system
influences the inflammatory development and progression
of B-cell mediated autoimmune diseases including SLE
[3,11,12]. In this study, we focused on the CXC α-chemo-
kine Stromal cell Derived Factor-1 (SDF-1)/CXCL12,
which together with its main receptor CXCR4, constitutes
the chemokine/receptor axis attracting the greatest level of
interest in autoimmunity [13]. Many leukocytes, including
B cells, express CXCR4 and CXCL12 is constitutively pro-
duced by stromal, epithelial, and endothelial cells notably
in lymphoid organs [14,15]. Given its ability to regulate B-
cell ontogeny, differentiation and homing, recent attention
has been directed to the CXCL12/CXCR4 axis in SLE
pathophysiology. CXCL12 is upregulated in the tubules
and glomeruli of nephritic kidneys from multiple lupus-
prone mouse models (e.g. NZB/W, BXSB, MRL.lpr) and
SLE patients as well [13,16,17]. Similarly, CXCR4 hyper-
expression or -activity has been reported in various
leukocyte subsets of lupus mouse models [13]. Thus, in
concert with CXCL12, CXCR4 could be pivotal for
leukocyte trafficking into damaged kidneys from mice with
lupus nephritis. In SLE patients, the situation is somewhat
puzzling, as contradictory results have been reported for
CXCR4 expression on peripheral blood lymphocytes. In-
deed, some studies have documented down- or up-
regulation of CXCR4 expression on SLE B cells, while
others failed to detect any change in membrane CXCR4
expression [8,13,16,18]. To our knowledge, there is cur-
rently no consensus on CXCR4 expression and its correl-
ation with SLE.
Little if anything is known about the expression and role
of CXCR7, the second receptor for CXCL12, in SLE
pathogenesis. CXCR7 binds with high affinity to CXCL12
and with lower affinity to Interferon-inducible T-cell
Alpha Chemoattractant (I-TAC)/CXCL11, but its signal-
ing capacities are still subject of debate [19,20]. Unlike
CXCR4, CXCR7 does not signal through the canonical
Gαi-protein pathways and thus, is unable to activate
conventional signaling events [20]. However, CXCR7
could act as a decoy receptor that is able to clear
CXCL12 from the surrounding medium [21-24]. CXCR7
is expressed on multiple cell types including endothelialand tumor cells and was shown to promote cell survival,
adhesion and tumor growth, suggesting a signaling po-
tential for this atypical receptor [19]. This may rely on
its reported ability to behave as an endogenous β-
arrestin-biased receptor or to complex with CXCR4,
forming heterodimers that regulate CXCL12 respon-
siveness [25-28]. The expression profile of CXCR7 in
mouse and human hematopoietic cells was recently
disputed [19,29-31]. It appears to be expressed on B
cells, tightly regulated during B-cell differentiation and
correlated with the capacity of memory B cells to
differentiate into Ab-secreting cells, i.e. PC, which are
increased in the blood of patient with active SLE
[6-8,21,30,32,33]. Whether CXCR7 dysregulation char-
acterizes SLE remains to be delineated.
The aim of this study was to examine the expression
of CXCR4 and CXCR7, together with CXCL12 respon-
siveness, in circulating B-cell subsets from Mexican
Mestizos SLE patients and age- and ethnicity-matched
healthy subjects. Our data reveal that both CXCR4 and
CXCR7 are downregulated on SLE B cells.
Methods
Ethics statement
The study was carried out in accordance with good clin-
ical practice guidelines, national laws and the Declaration
of Helsinki, and was approved by the Institutional Com-
mittee of Biomedical Research (Comité Institucional de
Investigación Biomédica en Humanos). All patients signed
an informed consent.
Patients, sample processing and cell culture
The study included 41 SLE patients (37 women and 4
men) with median age of 36 years (range: 21 to 62) and
median disease duration of 8 years (range: 1 to 27)
(Table 1). All patients were Mexican Mestizos [34],
recruited in the Department of Immunology and Rheuma-
tology of the Hospital “Instituto Nacional de Ciencias
Mèdicas y Nutriciòn Salvador Zubiràn” (Mexico City,
Mexico) and fulfilled at least four 1982 American Rheuma-
tism Association revised criteria for SLE [35]. Clinical dis-
ease activity was scored using the SLE Disease Activity
Index or SLEDAI [36]. 17 patients had inactive disease
(SLEDAI ≤ 3) and 24 patients with indices above 3 were
considered as having active disease as recently reported
[37]. The five patients who had neuropsychiatric (NP) or
central nervous system (CNS) history were inactive
regarding these manifestations at the time of the study.
All patients with renal involvement and SLEDAI > 4
had active disease at the time of the study, meaning that
most of active patients displayed active renal involve-
ment (n=20). Donors of control leukocytes consisted in
age- (median 41.4 years, range: 23 to 60 years) and sex-
biased (male/female ratio = 0.6) 45 healthy adult volunteers,
Table 1 Demographic, pathophysiological and treatment characterization of SLE patients
Parameters Inactive SLE (SLEDAI ≤ 3) Active SLE (SLEDAI > 3) P valuea
Total numbers (n) 17 24 N/Ab
Age at study (years)
Median 35 36 0.474
Range 21-62 25-50
Sex (n)
Female 15 22 N/A
Male 2 2 N/A
Duration of disease (years)
Median 8 8 0.577
Range 1-22 1-27
Clinical parameters (mean ± SD)
White Blood Cells (x109/L) 5.6 ± 1.8 4.9 ± 1.8 0.218
Clinical signs (n)
Muco-cutaneous 11 13 N/A
Haematological 8 12 N/A
Neurological/Psychiatric - 5 N/A
Serositis - 6 N/A
Renal 6 20 N/A
Joint 12 14 N/A
SLE activity (mean ± SD [range])
SLEDAI score 0.4 ± 0.2 [0-2] 9.1 ± 3.8 [4-18]*** <0.0001
B-cell subsets (mean ± SEM [range], x106/L)
Total CD19+ B cells 554.2 ± 121.9 [54-2077] 319.3 ± 73.9 [6-1303] 0.0585
CD27- naive B cells 398.6 ± 104.1 [17.9-1757] 217.1 ± 62.1 [0.7-1205]* 0.0403
Overall CD27+ B cells 146.2 ± 22.7 [35.1-323.2] 96.6 ± 16.8 [5.3-292.8] 0.0585
CD27+ memory B cells 127.5 ± 20.1 [30.3-273.6] 82.8 ± 15.2 [1.9-279.3] 0.0534
CD27high plasma B cells 19 ± 3.3 [4.9-49.6] 13.9 ± 2.6 [0.9-44.2] 0.0879
Treatment (n)
None 4 1 N/A
Prednisolone 5 20 N/A
Azathioprine 8 19 N/A
Methotrexate 2 1 N/A
Hydroxychloroquine 6 7 N/A
Mycophenolate Mofetil 2 3 N/A
Cyclophosphamide - 2 N/A
Leflunomide - 1 N/A
aMann-Whitney U-test; bN/A: Not Applicable.
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du Sang (Rungis, France) and 32 at the Hospital “Instituto
Nacional de Ciencias Mèdicas y Nutriciòn Salvador
Zubiràn”. Healthy subjects were seronegative for human im-
munodeficiency virus, hepatitis B or C virus, without evi-
dence of cancer, congenital heart disease or connective
tissue disorder. No differences were detected in CXCL12receptors expression and function in circulating lympho-
cytes from both French and Mexican healthy controls.
Within 2 hours after blood sampling either in Mexico or
France, peripheral blood mononuclear cells (PBMC) were
isolated in a similar fashion from heparin-treated blood
samples using Ficoll-Paque Plus (Amersham Biosciences
AB, Uppsala, Sweden) density gradient centrifugation and
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10% dimethylsulfoxide. After transportation in France,
SLE and healthy PBMC were defrozen by rapid thawing at
37°C in parallel with French samples and immediately
transferred to 10 mL FCS. Leukocytes were >90% viable
upon thawing, as assessed by trypan-blue exclusion. After
washing twice with 10 mL PBS 1X, PBMC were incubated
60 min at 37°C in RPMI medium supplemented with
20 mM HEPES and 0.5% bovine serum albumin (BSA), a
step allowing resensitization of chemokine receptors in-
cluding CXCR4 [38]. As specified in some experiments,
whole blood and PBMC were used right after collection.
Parental, CXCR4- and CXCR7-transduced HEK 293 T
(HEK) cells [29] were maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% FCS, glucose
(4.5 g/L), 10 mM HEPES, penicillin (100 units/mL) and
streptomycin (100 μg/mL) at 37°C in humidified air with
5% CO2.
Real-time RT-PCR analysis
Total cellular RNA was extracted from PBMC samples
using the RNeasy Plus Mini kit and genomic DNA
(gDNA) Eliminator columns (Qiagen, Courtaboeuf, France)
and reverse transcribed with pd(T)-15 and Moloney Mur-
ine Leukemia Virus reverse transcriptase (Fisher Bio-
block, Illkirch, France). RNA quality and integrity were
assessed by detecting both 18S and 28S ribosomal RNAs
in each sample and using a BioAnalyzer (Agilent), re-
spectively. As determined using the NanoDrop technol-
ogy, all samples displayed a RNA A260/280 ratio ~ 2.0
and a RNA Integrity Number > 7 and were then pro-
cessed for gene expression. Amplification of cDNAs
(1 μg) was performed by quantitative real-time PCR
reactions on a Light Cycler instrument (LC480, Roche
Diagnostics, Meylan, France) with the LightCycler 480
SYBR Green detection kit (Roche Diagnostics) using for-
ward (450-467) 5’-GACCGCTACCTGGCCATC-3’ and
reverse (743-761) 5’-GGCAGCCAACAGGCGAAGA-3’
primers for CXCR4 (311 bp), forward (8-29) 5’-TGCA
TCTCTTCGACTACTCAGA-3’ and reverse (94-113) 5’-
GGCATGTTGGGACACATCAC-3’ primers for CXCR7
(103 bp), and forward (214-223) 5’-GGGTCAGAAGGA
TTCCTATG-3’ and reverse (432-451) 5’-GGTCTCAAAC
ATGATCTGGG-3’ primers for β-actin (237 bp). We used
the LightCycler 480 Real-Time PCR system (Roche Diag-
nostics) with the following amplification scheme: 95°C
10 min and 40 cycles: 95°C 20 s, 60°C 15 s, 72°C 20 s. The
dissociation curve method was applied according to manu-
facturer’s protocol (60°C to 95°C) to ensure the presence of
a single specific PCR product. Relative quantification was
performed with the standard curve method as we previ-
ously used [33,39]. For each tested gene (i.e. CXCR4,
CXCR7 or β-actin), standard cDNAs from PHA-stimulated
PBMC were amplified along with sample cDNAs in thesame PCR run. Standard curves were generated by the
LC480 software (Roche Diagnostics). The threshold fluores-
cence common for all compared samples was set into the
exponential phase of the amplifications. The target mRNA
quantity in each sample was determined from the relative
standard curve (using sample Ct values) and expressed in
arbitrary units (AU) corresponding to the dilution factors
of the standard RNA preparation. Amplification efficiency
representative for each gene was determined using equation
of the standard curve as reported elsewhere [40]. Results
were expressed as CXCR4/β-actin on CXCR7/β-actin AU
ratios. Internal positive controls, consisting in CXCR4- or
CXCR7-transduced HEK cells, were run in parallel. We
controlled that no gDNA was amplified in all cDNA sam-
ples tested using the following intron-spanning primers:
forward (939-958) 5’-CACTCCCGCCCAATATACCC-3’
and reverse (1218-1237) 5’-ACACACAAAGAGGCCAC
TCC-3’ primers for CXCR4 (298 bp) and forward (353-
372) 5’-CTACAGCCACAGAAAGCGGA-3’ and reverse
(527-546) 5’-GGAAAGGAAAACTGCCAGCG-3’ primers
for CXCR7 (193 bp).
Flow-cytometric analysis
The frequency of each B-cell subset and membrane ex-
pression levels of both CXCR4 and CXCR7 were deter-
mined by four-color flow-cytometric analysis. For this
purpose, PBMC were incubated with the following mAbs
(unless specified from BD Pharmingen, Le Pont de Claix,
France): fluorescein isothiocyanate (FITC)-conjugated
mouse anti-human CD27 (clone M-T271), unconjugated
mouse anti-human CXCR7 (clone 9C4) followed by a
phycoerythrin (PE)-conjugated goat anti-mouse F(ab’)2
Ab (Dako, Trappes, France) as previously described [29],
PE-conjugated mouse anti-human CD38 (clone HIT2)
or CXCR7 (clone 11G8, R&D Systems, Lille, France or
clone 8F11-M16, BioLegend, San Diego, CA), peridinin
chlorophyll protein-Cy5 (PerCP-Cy5)-conjugated mouse
anti-human CD19 (clone HIB19), and allophycocyanin
(APC)-conjugated mouse anti-human CXCR4 (clone
12G5) or CD20 (clone 2H7). Isotype- and species-
matched Abs were used as negative controls. After wash
in PBS 1X, cells were analyzed on a FACSCalibur cyt-
ometer (BD Biosciences) using the CellQuest software
(BD Biosciences). At least 30,000 events were collected
for each analysis after gating on forward and side scatter
to select living lymphocytes. The frequencies of naive
(CD19+CD27-), memory (CD19+CD27+) and plasma
(CD19lowCD27high) B cells were calculated according to
statistical threshold sets in reference of control staining
(Figure 1A and Table 1), as previously reported [6].
CXCR4- or CXCR7-transduced HEK cells were used as
positive controls for specific staining. To assess total
pool of CXCR4 and CXCR7, i.e. membrane and intracel-
lular detection, PBMC were incubated with FITC-
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Figure 1 Increased frequency of circulating plasma cells in SLE patients. (A) Double staining with CD19 and CD27 was performed on PBMC
to delineate naive (CD19+CD27-) B cells, memory (CD19+CD27+) B cells and plasma (PC, CD19lowCD27high) cells. Thresholds and fluorescence
gates used for the statistical evaluation of CD27-, CD27+ and CD27high B lymphocytes are indicated as well as the corresponding frequency of
these subsets among total B cells. Expression of CD27 on CD19+ peripheral B cells is shown for a representative healthy blood donor and a
patient with active SLE. (B) Comparison of the frequencies of total B cells among PBMC and of the different B-cell subpopulations from SLE
patients (n = 41), distributed according to disease activity, i.e. inactive (n = 17) versus active (n = 24), and from healthy individuals (n = 45). The
proportions were determined by flow-cytometric analysis as shown in A. Results are depicted as box plots, with median (horizontal line within
each box) and 10th, 25th, 75th, and 90th percentiles (bottom bar, bottom of box, top of box, and top bar, respectively). Kruskal-Wallis H test and
associated P values are indicated. *P < .05 and ***P < .0005 compared with control B cells. §P < .05 compared with B cells from patients with
inactive SLE (as determined using the Mann–Whitney U-test). (C) Frequency (left panel) or total number (right panel) values obtained within
CD27high PC for each SLE patient were plotted as a function of SLEDAI scores. Correlation factor (r, Spearman’s) and P value are indicated.
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conjugated mouse anti-human CD19 mAbs, washed twice
in PBS 1X, fixed and permeabilized using the BD Cytofix/
Cytoperm Fixation/Permeabilization Kit (BD Biosciences)
according to the manufacturer’s instructions. Cells were
subsequently stained with 9C4 and 12G5 mAbs, or the cor-
responding isotype Ab, at room temperature for 30 min
and then analyzed by flow cytometry.
Chemotaxis assays
Chemotaxis was performed using a Transwell assay upon
CXCL12 or EBI1-Ligand Chemokine (ELC)/CCL19 induc-
tion as previously described [29]. Briefly, 3 × 105 PBMC in
150 μL RPMI medium supplemented with 20 mM HEPES
and 0.5% BSA were added to the upper chamber of a 6.5-
mm diameter, 5-μm pore polycarbonate Transwell culture
insert (Corning costar, Brumath, France). The same media
(600 μL) with or without CXCL12 (chemically synthesized
by Dr. F. Baleux, Unité de Chimie Organique, Institut
Pasteur, Paris, France) or CCL19 (R&D Systems) diluted
at various concentrations was placed in the lower cham-
ber. AMD3100 (Sigma-Aldrich, Saint-Quentin Fallavier,
France) was used at 1 μM to inhibit CXCR4-dependent
signaling. Input leukocytes that migrated to the lower
chamber after 2-hour incubation at 37°C in humidified air
with 5% CO2 were collected, stained with CD19, CD20,
CD38 and CD27 mAbs, and counted by flow cytometry.
The fraction of cells migrating across the polycarbonate
membrane was calculated as follows: [(number of cells mi-
grating to the lower chamber in response to chemokine or
medium)/(number of cells added to the upper chamber at
the start of the assay)] × 100.
Statistical analysis
Unless specified, all values are expressed as median (25th
and 75th percentiles). Data were analyzed using the Kruskal-
Wallis test for comparisons of values amongst at least three
groups, i.e. healthy controls, patients with inactive or active
SLE, when required, and non-parametrically using the
Mann–Whitney U-test (Prism software, GraphPad, La Jolla,
CA) for multiple comparisons and unpaired samples. Corre-
lations were determined by Spearman’s ranking. P values
lower than 0.05 were considered statistically significant.
Results
Altered B-cell distribution in the peripheral blood of SLE
patients
Cryopreserved PBMC of all 41 Mexican Mestizos patients
with SLE and 45 age- and ethnicity-matched independent
healthy subjects were analyzed by flow cytometry to deter-
mine the frequencies of naive, memory and plasma B cells.
Consistent with previous works [1,41], several abnormal-
ities of the B-cell compartment were detected in the periph-
eral blood of SLE patients including a B-cell lymphopeniathat predominantly affects naive B cells (Figure 1B and
Table 1). In contrast, a significant increase in the frequency
of PC was observed in patients with SLE (Figure 1A). Com-
parison of the proportions of the different B-cell subpopula-
tions from SLE patients distributed according to disease
activity, i.e. inactive (n = 17, SLEDAI ≤ 3) versus active (n =
24, SLEDAI > 3), revealed more marked B-cell alterations
in the blood of patients with active SLE. No significant cor-
relation could be detected between white blood cell count
and disease activity, duration or organ alteration (i.e. renal,
muco-cutaneous). In accordance with previous reports
[6,32], only the frequency of PC positively and significantly
correlated with the disease activity among peripheral B-cell
subsets (Figure 1C). Taken together, our data confirmed
perturbations of peripheral B-cell homeostasis, which were
more pronounced in patients with active disease. The im-
plication of CXCR4 and CXCR7 in the terminal differenti-
ation of B cells into Ab-secreting cells [15,30] prompted us
to investigate whether altered B-cell distribution in SLE was
associated with changes in CXCL12 receptors expression.Reduced levels of CXCR4 and CXCR7 mRNAs in SLE
leukocytes
We have set up real-time PCR analysis to quantify relative
levels of CXCR4 and CXCR7 mRNAs in SLE PBMC as
compared with those detected in the 45 healthy indivi-
duals. Transcripts encoding CXCR4 were readily detect-
able in leukocytes from healthy subjects (Figure 2A).
Likewise, CXCR7 mRNAs could be amplified in control
leukocytes (Figure 2B). Expression levels of both CXCR4
and CXCR7 mRNAs scattered over a large range among
donors, likely as the consequence of an inter-individual
variability [33,42,43]. However, the levels of CXCR4 and
CXCR7 transcripts were significantly decreased in leuko-
cytes from patients with active disease as compared to
control cells (Figures 2A and B). Amounts of CXCR4
and CXCR7 mRNAs seemed to negatively correlate with
SLEDAI scores, although this did not reach statistical
significance (Figures 2C and D). Disease duration and
muco-cutaneous manifestation did not impact on CXCR4
or CXCR7 expression. When comparing the group with
renal failure history (n=26) with that of non-renal-affected
patients (n=15), we did not find any significant differences
between both groups regarding CXCR4 or CXCR7 expres-
sion. Thus, our results unveiled a decrease in CXCR4 and
CXCR7 mRNA content in PBMC from SLE patients,
which is more pronounced in those with active disease.Defective membrane expression of CXCR4 and CXCR7
in SLE B lymphocytes
We next assessed whether such transcriptional anomaly
could result in reduced protein levels on circulating B cells.
A global flow-cytometric analysis of the expression of
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Figure 2 Decreased levels of CXCR4 and CXCR7 mRNAs in active SLE leukocytes. (A and B) The relative levels of CXCR4 (A) and CXCR7 (B)
transcripts in PBMC from SLE patients, distributed according to disease activity (i.e. inactive versus active), were compared by real-time PCR with
those from healthy individuals. Each individual sample has been run in triplicate. Results are expressed as CXCR4/β-actin or CXCR7/β-actin AU ratio
and presented as box plots with median values, 25th and 75th quartile and the range of values. Kruskal-Wallis H test and associated P values are
indicated. *P < .05 and **P < .005 compared with control leukocytes (as determined using the Mann–Whitney U-test). (C and D) Correlation
scatter plots of CXCR4 (C) or CXCR7 (D) mRNA levels and SLEDAI scores. Correlation factor (r, Spearman’s) and P value are indicated.
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subpopulations, i.e. naive B cells, memory B cells and PC,
in the control and SLE groups. As shown in Figure 3A,
most peripheral blood B cells of healthy donors expressed
CXCR4 (median value 82%, range: 41 to 99%). The per-
centage of CXCR4-positive cells decreases as control
B cells differentiate to PC (Figure 3B). In addition,
CXCR4 surface expression reached different levels on
total B cells (geometric mean fluorescence intensity
(MFI) median value 55, range: 11 to 217) and the dif-
ferent B-cell subsets as well (Additional file 1: Figure
S1A). In line with previous works [41], CXCR4 ex-
pression on circulating B cells was significantly lower
in SLE patients than in healthy controls (Figures 3A
and B and Additional file 1: Figure S1A). Because the
decrease in CXCR4 expression could be due to
changes in the proportion of B-cell subsets or varia-
tions in expression levels within subsets, we per-
formed an intra-subset analysis. Both frequencies of
CXCR4-positive B cells and expression levels of
CXCR4 within naive, memory and PC subsets were
markedly reduced in patients with SLE (Figure 3B
and Additional file 1: Figure S1A). Strikingly, B cells
from patients with either inactive or active disease
displayed a comparable defect in cell surface CXCR4
expression in the three subsets analyzed. Therefore,
and similarly to the disease duration or organ manifestation
(i.e. renal, muco-cutaneous), the disease activity did not im-
pact on the level of CXCR4 expression. Consequently, nosignificant correlation could be detected between SLEDAI
scores and CXCR4 expression on total B cells (Figures 3C
and D).
We concomitantly assessed CXCR7 protein expression
on B-cell subpopulations using the 9C4 mAb, which has
been previously reported to specifically react with
human CXCR7 [29,30,33]. Confirming this, the 9C4
mAb stained CXCR7-transduced, but not parental, HEK
cells (Figure 4A). Compared with CXCR4, we observed
only low levels of CXCR7 (median value 4.8%, range: 0.2
to 27%) at the surface of CD19+-gated PBMC from
healthy individuals (Figure 4B). CXCR7 remained scarcely
expressed on maturating, including memory, B cells. Simi-
lar staining patterns were obtained using commercially
available 11G8 and 8F11-M16 anti-CXCR7 mAbs. CXCR7
expression on naive and overall CD27+ B cells was still
significantly lower in SLE patients than in healthy con-
trols. However, as for CXCR4, there was no correlation
between CXCR7 expression levels and the clinical activity
of SLE (Figure 4C).
When we compared patients with (n=25) or without
(n=16) prednisolone-based treatment, no significant
differences were found between both groups in term of
receptors levels. As most active patients received 30 or
50 mg/day prednisolone, we thus cannot assigned an
impact of steroids on CXCR4 or CXCR7 expression.
Taken together, these findings unraveled a down-regulation
of CXCL12 receptors on circulating B-cell subsets from
SLE patients. We next addressed whether this loss of
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Figure 3 Loss of CXCR4 expression on SLE B cells. (A) Membrane expression of CXCR4 on CD19+-gated PBMC from healthy and SLE subjects
was determined by flow cytometry using the APC-conjugated 12G5 (empty histograms) or isotype control (filled histogram) mAb. Displayed data
are representative plots of the mean fluorescence intensity (MFI) of CXCR4 at the surface of total B cells from a healthy individual and two
patients with either inactive or active SLE. (B) The percentage of total (CD19+) B cells, naive (CD19+CD27-) B cells, memory (CD19+CD27+) B cells
and PC (CD19lowCD27high) expressing CXCR4 in healthy and SLE subjects are given. Box plots show the median values, 25th and 75th quartile and
the range of values. Kruskal-Wallis H test and associated P values are indicated. ***P < .0005 compared with control B cells (as determined using
the Mann–Whitney U-test). (C and D) CXCR4-positive fraction (C) or MFI (D) values obtained within total B cells for each SLE patient were plotted
as a function of SLEDAI scores. Correlation factor (r, Spearman’s) and P value are indicated.
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Figure 4 Altered CXCR7 expression on SLE B cells. (A) Surface expression of CXCR7 on CD19+-gated PBMC from healthy and SLE subjects was
determined by flow cytometry using the unconjugated 9C4 (empty histograms) or isotype control (filled histograms) mAb followed by a PE-
conjugated goat anti-mouse F(ab’)2 Ab. CXCR7-transduced (versus parental) HEK 293 T (HEK) cells were used as a positive control for staining. Displayed
data are representative plots of the MFI of CXCR7 at the surface of total B cells from a healthy individual and two patients with either inactive or active
SLE (left panel) or of HEK cells transduced with CXCR7 or left untransduced (right panel). (B) The percentage of total (CD19+) B cells, naive (CD19+CD27-)
B cells, memory (CD19+CD27+) B cells and PC (CD19lowCD27high) expressing CXCR7 in healthy and SLE subjects are shown. Box plots show the median
values, 25th and 75th quartile and the range of values. Kruskal-Wallis H test and associated P values are indicated. *P < .05, **P < .005 and ***P < .0005
compared with control B cells (as determined using the Mann–Whitney U-test). (C) CXCR7-positive fraction values obtained within total B cells for each SLE
patient were plotted as a function of SLEDAI scores. Correlation factor (r, Spearman’s) and P value are indicated.
Biajoux et al. Journal of Translational Medicine 2012, 10:251 Page 9 of 16
http://www.translational-medicine.com/content/10/1/251
Biajoux et al. Journal of Translational Medicine 2012, 10:251 Page 10 of 16
http://www.translational-medicine.com/content/10/1/251membrane CXCR4 and CXCR7 expression was associated
with an abnormal intracellular compartmentalization of the
receptors.
Intracellular localization of CXCL12 receptors in SLE B
lymphocytes
CXCR4 is mostly expressed at the surface of circulating
leukocytes from healthy donors, while its intracellular
pool is rather minor [44,45]. By contrast, CXCR7 is
rarely, or even not, expressed at the membrane of
human and mouse leukocytes [21,29,30,46]. Some stud-
ies indicated that CXCR7 is predominantly localized
underneath the plasma membrane [47], while others
failed to detect it intracellularly [31]. Stimulated by this
puzzling picture of the intracellular detection of CXCR4
and CXCR7, we assessed by flow cytometry the expres-
sion of both receptors in CD19+-gated PBMC after
permeabilization. This step allowed detecting relative
total, i.e. both cell surface and intracellular, pools of
CXCR4 and CXCR7 in B cells. As shown in Figure 5A,
the majority of total B cells from healthy individuals
coexpressed CXCR4 and CXCR7 (median value 97%,
range: 51.9 to 99%). About 1% and 3% of B cells only
expressed CXCR4 or CXCR7, respectively, whereas
roughly < 1% of the cells expressed neither CXCR4 nor
CXCR7. A similar pattern was found in the different
B-cell subsets (Figure 5B). These findings, combined
with those displayed in Figures 3 and 4, confirmed the
differential cellular compartmentalization of both
CXCR4 and CXCR7, i.e. predominant cell surface detec-
tion of CXCR4 (>80% total pool) and intracellular
localization of CXCR7 (>90% total pool).
The situation was somewhat different in permeabi-
lized PBMC from SLE patients. The fraction of total B
cells coexpressing both receptors was slightly decreased
by ~20-30% relative to control cells, while the propor-
tion of B cells expressing only CXCR4 or CXCR7 was
significantly increased (Figure 5). The defect in total
CXCR4 expression was comparable among naive, mem-
ory and PC subsets from patients with either inactive
or active disease. These data further revealed a signifi-
cant intracellular detection of both CXCR4 (>60% total
pool) and CXCR7 (>90% total pool) in SLE B cells. In
line with this, geometric MFI values for total pools of
CXCR4 and CXCR7 were roughly comparable in B cells
from healthy and SLE subjects, while membrane ex-
pression levels of CXCR4 were decreased on SLE B
cells (Additional file 1: Figure S1). Collectively, our
findings established that naive and overall CD27+ B
cells from both healthy and SLE individuals displayed a
nearly exclusive expression of CXCR7 in cytosolic com-
partments. The loss of membrane CXCR4 expression in
SLE B cells was accompanied by its abnormal intracel-
lular localization.Impaired CXCL12-promoted chemotaxis of SLE B lymphocytes
We thus questioned whether impaired compart-
mentalization of CXCL12 receptors, i.e. decreased at the
membrane and increased at the intracellular level, in SLE B
cells impacted on CXCL12 responsiveness. We investigated
the migratory response of CD19+-gated PBMC from
healthy and SLE subjects to CXCL12 using a Transwell-
based chemotaxis assay. Addition of CXCL12 resulted in a
dose-dependent chemotactic response of both control and
SLE B cells (Figure 6A). However, SLE B cells displayed
weaker migratory responses to all concentrations tested,
indicating a lower efficiency of chemotaxis to CXCL12. In
contrast, CCR7-dependent migration following CCL19
stimulation was observed to be in the same range for SLE
and control B cells. We then compared chemotactic
responses of the different B-cell subsets from patients with
either inactive or active SLE to those obtained with control
cells. The CXCL12 dose was chosen so that migration was
detectable for B cells harboring low CXCL12 receptors
expression (i.e. SLE group) without reaching saturating
concentrations for B cells with higher receptor expression
(i.e. control group). Upon exposure to 30 nM CXCL12, the
percentage of specific migration of B cells from healthy
donors was of ~15%, ~30% and ~40% in the naive, memory
and PC subsets, respectively (Figure 6B). Remarkably, cir-
culating B cells from patients with inactive or active disease
shared an impaired CXCL12-promoted chemotaxis, with a
significant reduction (> 60% as compared to control cells)
of specific migration in the three subsets analyzed. Such
decrease in migration efficiency was consistent with the
severe decrease in CXCR4 expression observed on all SLE
B-cell subsets. The residual migration of SLE B cells upon
CXCL12 exposure was totally inhibited by the specific
CXCR4 antagonist AMD3100 [48]. Overall, these findings
suggested that the defect in membrane CXCR4 expression
contributes to the loss of CXCL12 responsiveness of SLE B
lymphocytes.
Discussion
In the present study, we provided novel insights to SLE
pathophysiology based on the systematic evaluation of
CXCL12 receptors expression in circulating B cells from
a large cohort of 41 Mexican Mestizos patients. Our
findings revealed reduced levels of CXCR4, and to a
lesser extent of CXCR7, transcripts in SLE PBMC com-
pared to controls. SLE was associated with a strong
defect of membrane CXCR4 expression in naive and
Ab-secreting B cells accompanied by an abnormal intra-
cellular detection of CXCR4. CXCR7 was scarcely
expressed on control and SLE B cells and predominantly
localized in cytosolic compartments. Altered receptor
compartmentalization was associated with an impaired
CXCL12-promoted migration of SLE B cells. As the ma-
jority (n=23) of active patients were treated with at least
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Figure 5 Intracellular localization of CXCR4 and CXCR7 in SLE B cells. (A) Total pools of CXCR4 and CXCR7 were simultaneously detected by
flow-cytometric analysis in CD19+-gated PBMC from healthy and SLE subjects. Staining was performed on fixed and permeabilized leukocytes
with both 9C4 (PE) and 12G5 (APC) mAbs. Quadrants were set on controls stained with the corresponding isotype control. Representative dot-
plots demonstrating coexpression of CXCR4 and CXCR7 in total B cells from a healthy individual and two patients with either inactive or active
SLE are shown. (B) The proportions (mean ± SEM) of total (CD19+) B cells, naive (CD19+CD27-) B cells, memory (CD19+CD27+) B cells and PC
(CD19lowCD27high) expressing CXCR4 and/or CXCR7 in healthy and SLE subjects are given. *P < .05, **P < .005 and ***P < .0005 compared with
control B cells.
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http://www.translational-medicine.com/content/10/1/251two drugs, we cannot assess the effects of each immuno-
suppressive therapy on CXCL12 receptors expression
and function. Neither disease activity or duration nor
muco-cutaneous and renal manifestations significantly
influenced CXCR4 and CXCR7 protein expression. Con-
versely, when we applied a single cut-off at 21.79% and
0.83%, the respective median value for CXCR4- and
CXCR7-positive B cells in the entire cohort, for the clas-
sification of patients displaying low or high levels of
CXCL12 receptors expression, no clinical difference was
found between the two groups (P = 0.52 and P = 0.21
for CXCR4 and CXCR7 respectively, Mann–Whitney
U-test). Thus, it would be worthwhile to investigate
groups of active patients with joint/cutaneous,
hematological, CNS, and pure renal involvement in
order to differentiate how these manifestations impact
on receptors expression.CXCR4 is involved in B-cell differentiation and hom-
ing as well as in the inflammatory development and pro-
gression of B-cell mediated autoimmune disorders
including SLE [3,13]. In line with previous works
[13,15,42], we observed that the vast majority of circulat-
ing total B cells from healthy donors stained for CXCR4,
while the frequency of CXCR4-positive B cells decreased
upon differentiation. Similarly, an inverse correlation of
membrane CXCR4 expression and maturating stage of B
cells was detected in SLE patients. However, the fre-
quency of CXCR4-positive B cells within naive, memory
and PC subsets was significantly decreased, suggesting
that the defect in membrane CXCR4 expression results
from an intrinsic CXCR4 anomaly rather than the
expansion of a CXCR4-negative B-cell subpopulation.
Circulating B cells from patients with either inactive
or active disease displayed a comparable defect in
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Figure 6 Loss of CXCL12 responsiveness in SLE B cells. (A and B) PBMC from independent healthy individuals (n = 9) and patients (SLE, n = 14),
with either inactive (n = 7) or active (n = 7) disease, were tested for their ability to migrate in response to the indicated concentration (A) of chemokine or
30 nM of CXCL12 (B). Transmigrated cells recovered in the lower chamber were stained with mAbs specific for CD19, CD20, CD38 and CD27 antigens and
counted by flow cytometry. Inhibition of cell migration by AMD3100 added in both chambers is shown. Results (mean ± SEM) are from 4 independent
experiments and expressed as the percentage of input total (gated CD19+) B cells (A and B, upper left), naive (gated CD19+CD20+CD27-CD38-) B cells
(B, upper right), memory (gated CD19+CD20+CD27+CD38-) B cells (B, lower left) or PC (gated CD19lowCD20lowCD27highCD38high) (B, lower right) that
migrated to the lower chamber. *P < .05, **P < .005 and ***P < .0005 compared with control B cells.
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http://www.translational-medicine.com/content/10/1/251membrane CXCR4 expression, indicating that the dis-
ease activity did not impact on the level of CXCR4 ex-
pression. Thus, our findings provided evidence that SLE
B cells display a loss of membrane CXCR4 expression.
In agreement with this, Henneken and coworkers previ-
ously showed a decrease in CXCR4-positive naive and
overall CD27+ B cells from 4 SLE patients [41]. Because
CXCR4 is virtually expressed on all B-cell subsets,
changes in CXCL12 responsiveness that occur through-
out lymphocyte ontogeny were proposed to result from
differences in the activation of CXCR4-mediated signal-
ing [15]. For instance, CXCR4 expression is downregu-
lated upon B-cell receptor engagement [49]. It is
tempting to speculate that the loss of CXCR4 expression
in SLE reflects, at least in part, chronic in vivo B-cell
activation.While there is a relative consensus on CXCR4 anom-
aly in B cells of several mouse models of lupus nephritis
[13,50], the situation is still unclear in humans. Indeed,
Wang and coworkers observed increased CXCR4 levels
in circulating B and T cells from 31 SLE patients [16].
These findings have been partially confirmed by Rodriguez-
Bayona and coworkers who detected in a larger cohort
composed of 69 patients a slight increase in CXCR4 expres-
sion restricted to non-switched memory B cells and sparing
other B-cell subsets [8]. The reasons for discrepancies on
CXCR4 profiles between our work and principally that of
Wang and coworkers are unclear but may relate to diffe-
rences in sample handling or ethnical origin of patients
[51]. Indeed, whereas Wang and coworkers performed
CXCR4 staining on whole blood [16], we analyzed CXCL12
receptors patterns on PBMC, indicating that the Ficoll-
Biajoux et al. Journal of Translational Medicine 2012, 10:251 Page 13 of 16
http://www.translational-medicine.com/content/10/1/251based isolation could constitute a cause for the differences
on CXCR4 expression. However, and in contrast to the
recent study by Nieto and coworkers [38], we found only
discrete differences in CXCR4 expression at the surface
of control B cells after cell isolation as compared to
whole blood samples (Additional file 2: Figure S2). Cryo-
preservation of PBMC might also constitute a source of
changes in labile phenotypic markers and B-cell subset
distribution. Recently, Faint and coworkers showed that
cryopreserved sample batching, and subsequent thawing
for deferred analysis, did not alter the proportion of
lymphocyte subsets but led to an increased CXCR4
expression on lymphocytes [52]. In our hands, the cryo-
preservation step indeed influenced positively CXCR4
expression on control B cells (Additional file 2: Figure
S2). Thus, this process cannot solely explain the CXCR4
down-regulation we describe here. SLE represents a
polygenic disease for which several clinical differences
among ethnic groups have been documented [2,53,54].
Having focused on a cohort of 41 Mexican Mestizos
patients [34], we differed from other studies, which have
assessed CXCR4 expression on lymphocytes from patients
with various ethnical origins [8,16]. Therefore, we cannot
rule out that heterogeneity in the genetic background could
account for contradictory results.
The molecular basis underlying the defect in CXCR4
expression on SLE B cells is unclear but might involve
both impaired receptor synthesis and intracellular traf-
ficking. We unveiled decreased CXCR4 expression in
PBMC from SLE patients. Such transcriptional anomaly,
which is consistent with a recent study [18], could result
in reduced protein levels in circulating leukocytes
including the B-cell compartment. Whether epigenetic
(e.g. promoter hypermethylation) or post-transcriptional
(e.g. microRNA) regulatory mechanisms account for the
decrease in the steady-state levels of CXCR4 mRNAs will
be the focus of future investigations on sorted B cells
from patients. Our findings were enough indicative to
delineate how such transcriptional anomaly could im-
pact on protein levels, especially in circulating B cells.
Flow-cytometric analysis revealed a significant decrease
in the total pool of CXCR4 together with an impaired
compartmentalization of the receptor, i.e. reduced at the
cell surface and increased at the intracellular level, in all
B-cell subsets from SLE patients irrespective of their
disease activity status. The different cytokine milieu in
SLE patients could alter the expression and activity of
CXCR4. An increase in serum TNF-α and type I IFN
levels is characteristic of SLE [11] and both cytokines
are known to down-regulate CXCR4 [55,56]. The pro-
inflammatory cytokine IL-17 might be involved in such
phenomenon, as it increased in the serum of SLE
patients [57] and down-modulated the responsiveness of
germinal center B cells to Cxcl12 in autoimmune BXD2mice [58]. Interestingly, an increase of CXCL12 in the
serum of SLE patients has been reported [59]. Since
CXCR4 engagement upon CXCL12 stimulation paradig-
matically leads to receptor internalization, one can
speculate that chronic exposure to CXCL12 is another
potential explanation for abnormal CXCR4 expression
on autoreactive B cells.
The study was extended to the expression of CXCR7,
which is another receptor for CXCL12 but, unlike
CXCR4, it has never been investigated in the context of
lupus pathogenesis. Surface expression of CXCR7 is well
documented on activated endothelium, fetal liver cells,
neurons and multiple cancer cells [19,60]. Many groups
have detected CXCR7 products in mouse and human
leukocytes, although one study challenged this view
[31,33]. Our real-time PCR-based analysis permitted to
readily detect mRNAs encoding CXCR7 in PBMC from
healthy subjects, further corroborating previous studies
demonstrating unambiguously transcript amplification
in mouse and human monocytes, dendritic cells, CD4+
T cells, neutrophils and B cells [19,30,33,61,62]. Never-
theless, SLE leukocytes displayed a slight decrease in the
steady-state level of CXCR7 transcripts. Further in-depth
studies are required to determine whether transcrip-
tional regulatory mechanisms account for heterogeneous
CXCR7 expression in SLE. Like for CXCR4, we found no
differences in CXCR7 expression at the surface of con-
trol B cells after Ficoll-based cell isolation as compared
to whole blood samples (Additional file 3: Figure S3). In
contrast, the cryopreservation step led to a reduced
CXCR7 expression on B cells. Thus, we cannot exclude
that cryopreserved sample batching contributes to low
levels of CXCR7 on SLE B cells.
Intracellular compartmentalization of CXCL12 recep-
tors was simultaneously assessed by flow cytometry after
cell permeabilization, and in line with previous works
[20,47], unraveled that CXCR7 predominantly localized
in cytosolic compartments of B-cell subsets from healthy
and SLE subjects. Such peculiar intracellular pattern is
consistent with the notion that CXCR7 rapidly cycles be-
tween the plasma membrane and intracellular compart-
ments either spontaneously or upon exposure to its
ligand [20,24,28,47]. The main function of endothelium-
expressed CXCR7 is likely sequestration of CXCL12 as
proposed in homeostatic and pathological, including auto-
immune, conditions [24,46]. Additionally, mouse CXCR7
seems to function as a sink for CXCL12 and contributes
to marginal zone B-cell retention as well as kidney devel-
opment [22,63]. Recently, we identified CXCR7 as an ac-
tive scavenger for CXCL12 on human tonsil-derived B
cells [33]. Although the relevance of this activity in human
B-cell homeostasis remains to be determined, one can
speculate that CXCR7 acts as a decoy receptor in B cells,
thereby clearing CXCL12 from the surrounding medium
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http://www.translational-medicine.com/content/10/1/251and controlling CXCR4 expression and/or signaling. A
crosstalk between intracellular CXCR4 and CXCR7 could
also be involved in the modulation of CXCL12 activities as
previously proposed [47]. Finally, we cannot exclude that
defective CXCR4 and CXCR7 expression in SLE leukocytes
impacts on the anterograde trafficking, i.e. from synthesis
in the endoplasmic reticulum to the plasma membrane, of
both receptors, resulting in their altered cellular distribu-
tion [64]. Studying the relevance of CXCR7 in B-cell
biology was not in the scope of this study but clearly
deserves further investigations using selective antagonists
for CXCR4 and CXCR7.
Conclusions
Our findings highlight a previously unappreciated down-
regulation of CXCR4 and CXCR7 on circulating B cells
from SLE patients. Such anomaly is associated with
intracellular localization of both receptors and a loss of
CXCL12 responsiveness. This is the first study assessing
simultaneously the status of CXCL12 receptors in
autoimmune-biased B cells. This work offers important
pathophysiological insights into the migratory behavior
of autoreactive B cells from SLE patients, potentially
permitting new therapeutic avenues.
Additional files
Additional file 1: Figure S1. Distribution of CXCR4 and CXCR7 in SLE B
cells. (A) Expression of CXCR4 on CD19+-gated PBMC from SLE patients
(n = 41), distributed according to disease activity, i.e. inactive (n = 17) versus
active (n = 24), and healthy individuals (n = 45) was determined by flow-
cytometric analysis (FACSCalibur, BD Biosciences) using the APC-conjugated
12G5 mAb. The geometric mean fluorescence intensity (MFI) of CXCR4 at
the surface of total (CD19+) B cells, naive (CD19+CD27-) B cells, memory
(CD19+CD27+) B cells and PC (CD19lowCD27high) from healthy and SLE
subjects are displayed. (B) Total pools of CXCR4 and CXCR7 were detected
by flow cytometry by staining fixed and permeabilized leukocytes with 9C4
(PE) and 12G5 (APC) mAbs. The geometric MFI of CXCR4 or CXCR7 was
evaluated in total B cells. Box plots show the median values, 25th and 75th
quartile and the range of values. Kruskal-Wallis H test and associated P
values are indicated. ***P < .0005 compared with control B cells. §P < .05
compared with B cells from patients with inactive SLE (as determined using
the Mann–Whitney U-test).
Additional file 2: Figure S2. Sample processing modulates membrane
CXCR4 expression. (A) Membrane expression of CXCR4 on control
CD19+-gated B cells was determined by flow-cytometric (FACS Fortessa, BD
Biosciences) analysis using the PE-conjugated 12G5 (empty histograms) or
isotype control (filled histogram) mAb. Displayed data are representative
plots of the MFI of CXCR4 at the surface of total B cells from 4 independent
healthy Caucasian women (age median 35 years, range: 24 to 47 years)
obtained either after staining on whole blood (Blood) or fresh (Ficoll) or
cryopreserved (Cryo) PBMC. (B) The percentage of total (CD19+) B cells,
naive (CD19+CD27-) B cells, memory (CD19+CD27+) B cells and plasma cells
(CD19low CD27high) expressing CXCR4 are given. Box plots show the median
values, 25th and 75th quartile and the range of values. (C) The geometric
MFI of CXCR4 was evaluated for all aforementioned B-cell subsets. *P < .05,
**P < .005 and ***P < .0005 compared with whole blood-gated B cells.
Additional file 3: Figure S3. Sample processing modulates membrane
CXCR7 expression. (A) Surface expression of CXCR7 on CD19+-gated B
cells from 4 independent healthy Caucasian women was determined by
flow cytometry using the unconjugated 9C4 (empty histograms) orisotype control (filled histograms) mAb followed by a PE-conjugated goat
anti-mouse F(ab’)2 Ab. Displayed data are representative plots of the MFI
of CXCR7 at the surface of total B cells obtained either after staining on
whole blood (Blood) or fresh (Ficoll) or cryopreserved (Cryo) PBMC.
(B) The percentage of total (CD19+) B cells, naive (CD19+ CD27-) B cells,
memory (CD19+ CD27+) B cells and plasma cells (CD19low CD27high)
expressing CXCR7 are given. Box plots show the median values, 25th and
75th quartile and the range of values. (C) The geometric MFI of CXCR7
was evaluated for all B-cell subsets. *P < .05 and **P < .005 compared
with whole blood-gated B cells.
Abbreviations
Ab: Antibody; APC: Allophycocyanin; BSA: Bovine serum albumin;
CNS: Central nervous system; FCS: Fetal calf serum; FITC: Fluorescein
isothiocyanate; MFI: Mean fluorescence intensity; NP: Neuropsychiatric;
PBMC: Peripheral blood mononuclear cells; PC: Plasma cells;
PE: Phycoerythrin; PerCp-Cy5: Peridinin chlorophyll protein-Cy5; SDF-
1: Stromal cell Derived Factor-1; SLE: Systemic Lupus Erythematosus;
SLEDAI: Systemic Lupus Erythematosus Disease Activity Index.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conceived and designed the experiments: VB, AB, DE and KB. Performed the
experiments: VB, AB, CF and KB. Analyzed the data: VB, AB, CF and KB. Wrote
the paper: VB, AB and KB. Provided funding: DE and KB. Provided
experimental tools and contributed to manuscript editing: VM, MT and LL.
Provided patient samples and clinical features: GL, JJ-O and LL. All authors
read and approved the final manuscript.
Acknowledgements
We thank V. Godié (Université Paris-Sud, Laboratoire "Cytokines, Chimiokines
et Immunopathologie", INSERM UMR_S996, Clamart, France) for excellent
technical assistance, H. Tharinger (Plateforme d’Immunomonitorage, Institut
Paris-Sud d’Innovation Thérapeutique, Clamart) for editing the manuscript,
and Dr. F. Baleux (Unité de Chimie Organique, Institut Pasteur, Paris, France)
for providing us with CXCL12. We are grateful to Drs. V. Machelon and F.
Bachelerie (INSERM UMR_S996) for critical reading of the manuscript. This
work was supported by the Assistance Publique-Hôpitaux de Paris (AP-HP,
grant number 07018) and the Agence Nationale de la Recherche (ANR, grant
number 2010 JCJC 1104 01). V.B., A.B., C.F., V.M., D.E. and K.B. are members of
the Laboratory of Excellence LERMIT supported by a grant from ANR
(Investissements d’Avenir). V.B., A.B. and C.F. are fellowship recipients from
the Fondation pour la Recherche Médicale, the French Ministry and the DIM
Biothérapies, respectively. M.T. was supported by funds obtained from the
Gottfried und Julia Bangerter-Rhyner-Stiftung, Basel, the Helmut Horten
Foundation and the Fondazione Ticinese per la Rcicerca sul Cancro.
Author details
1Université Paris-Sud, Laboratoire "Cytokines, Chimiokines et Immunopathologie",
UMR_S996, Clamart, France. 2INSERM, Laboratory of Excellence in Research on
Medication and Innovative Therapeutics (LERMIT), Clamart, France. 3Service de
Médecine Interne et d’Immunologie Clinique, AP-HP, Hôpital Antoine-Béclère,
Clamart, France. 4Institute for Research in Biomedicine, Bellinzona, Switzerland.
5Department of Immunology and Rheumatology, Instituto Nacional de Ciencias
Mèdicas y Nutriciòn Salvador Zubiràn, Mexico City, Mexico. 6Service de
Microbiologie-Immunologie Biologique, AP-HP, Hôpital Antoine-Béclère, Clamart,
France.
Received: 18 September 2012 Accepted: 14 December 2012
Published: 18 December 2012
References
1. Rahman A, Isenberg DA: Systemic lupus erythematosus. N Engl J Med
2008, 358:929–939.
2. Deng Y, Tsao BP: Genetic susceptibility to systemic lupus erythematosus
in the genomic era. Nat Rev Rheumatol 2010, 6:683–692.
3. Mitchison NA, Wedderburn LR: B cells in autoimmunity. Proc Natl Acad Sci
USA 2000, 97:8750–8751.
Biajoux et al. Journal of Translational Medicine 2012, 10:251 Page 15 of 16
http://www.translational-medicine.com/content/10/1/2514. Nashi E, Wang Y, Diamond B: The role of B cells in lupus pathogenesis. Int
J Biochem Cell Biol 2010, 42:543–550.
5. Deshmukh US, Bagavant H, Fu SM: Role of anti-DNA antibodies in the
pathogenesis of lupus nephritis. Autoimmun Rev 2006, 5:414–418.
6. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, Valet
G, Lipsky PE, Dorner T: Correlation between circulating CD27high plasma
cells and disease activity in patients with systemic lupus erythematosus.
Arthritis Rheum 2003, 48:1332–1342.
7. Pisetsky DS, Grammer AC, Ning TC, Lipsky PE: Are autoantibodies the
targets of B-cell-directed therapy? Nat Rev Rheumatol 2011, 7:551–556.
8. Rodriguez-Bayona B, Ramos-Amaya A, Perez-Venegas JJ, Rodriguez C, Brieva
JA: Decreased frequency and activated phenotype of blood CD27 IgD
IgM B lymphocytes is a permanent abnormality in systemic lupus
erythematosus patients. Arthritis Res Ther 2010, 12:R108.
9. Daridon C, Blassfeld D, Reiter K, Mei HE, Giesecke C, Goldenberg DM,
Hansen A, Hostmann A, Frolich D, Dorner T: Epratuzumab targeting of
CD22 affects adhesion molecule expression and migration of B-cells in
systemic lupus erythematosus. Arthritis Res Ther 2010, 12:R204.
10. Thelen M, Stein JV: How chemokines invite leukocytes to dance. Nat
Immunol 2008, 9:953–959.
11. Ohl K, Tenbrock K: Inflammatory cytokines in systemic lupus
erythematosus. J Biomed Biotechnol 2011, 2011:432595.
12. Ezzat M, El-Gammasy T, Shaheen K, Shokr E: Elevated production of serum
B-cell-attracting chemokine-1 (BCA-1/CXCL13) is correlated with
childhood-onset lupus disease activity, severity, and renal involvement.
Lupus 2011, 20:845–854.
13. Chong BF, Mohan C: Targeting the CXCR4/CXCL12 axis in systemic lupus
erythematosus. Expert Opin Ther Targets 2009, 13:1147–1153.
14. Ansel KM, Cyster JG: Chemokines in lymphopoiesis and lymphoid organ
development. Curr Opin Immunol 2001, 13:172–179.
15. Palmesino E, Moepps B, Gierschik P, Thelen M: Differences in CXCR4-
mediated signaling in B cells. Immunobiology 2006, 211:377–389.
16. Wang A, Guilpain P, Chong BF, Chouzenoux S, Guillevin L, Du Y, Zhou XJ,
Lin F, Fairhurst AM, Boudreaux C, et al: Dysregulated expression of CXCR4/
CXCL12 in subsets of patients with systemic lupus erythematosus.
Arthritis Rheum 2010, 62:3436–3446.
17. Balabanian K, Couderc J, Bouchet-Delbos L, Amara A, Berrebi D, Foussat A,
Baleux F, Portier A, Durand-Gasselin I, Coffman RL, et al: Role of the
chemokine stromal cell-derived factor 1 in autoantibody production and
nephritis in murine lupus. J Immunol 2003, 170:3392–3400.
18. Lugar PL, Love C, Grammer AC, Dave SS, Lipsky PE: Molecular
characterization of circulating plasma cells in patients with active
systemic lupus erythematosus. PLoS One 2012, 7:e44362.
19. Thelen M, Thelen S: CXCR7, CXCR4 and CXCL12: an eccentric trio?
J Neuroimmunol 2008, 198:9–13.
20. Ulvmar MH, Hub E, Rot A: Atypical chemokine receptors. Exp Cell Res 2011,
317:556–568.
21. Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes HG,
Rot A, Thelen M: CXCR7 functions as a scavenger for CXCL12 and
CXCL11. PLoS One 2010, 5:e9175.
22. Wang H, Beaty N, Chen S, Qi CF, Masiuk M, Shin DM, Morse HC 3rd: The
CXCR7 chemokine receptor promotes B-cell retention in the splenic
marginal zone and serves as a sink for CXCL12. Blood 2011, 119:465–468.
23. Luker KE, Steele JM, Mihalko LA, Ray P, Luker GD: Constitutive and
chemokine-dependent internalization and recycling of CXCR7 in breast
cancer cells to degrade chemokine ligands. Oncogene 2010, 29:4599–4610.
24. Hoffmann F, Muller W, Schutz D, Schulz S, Stumm R: The CXCR7 C-terminal
domain mediates efficient CXCL12 uptake and degradation. J Biol Chem
2012, 287:28362–28377.
25. Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP, Gerard C, Lefkowitz
RJ: Beta-arrestin- but not G protein-mediated signaling by the "decoy"
receptor CXCR7. Proc Natl Acad Sci USA 2010, 107:628–632.
26. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B: CXCR7
heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein
signaling. Blood 2009, 113:6085–6093.
27. Decaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P: CXCR7/
CXCR4 Heterodimer Constitutively Recruits {beta}-Arrestin to Enhance
Cell Migration. J Biol Chem 2011, 286:32188–32197.
28. Canals M, Scholten DJ, de Munnik S, Han MK, Smit MJ, Leurs R: Ubiquitination
of CXCR7 controls receptor trafficking. PLoS One 2012, 7:e34192.29. Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B,
Arenzana-Seisdedos F, Thelen M, Bachelerie F: The chemokine SDF-1/
CXCL12 binds to and signals through the orphan receptor RDC1 in T
lymphocytes. J Biol Chem 2005, 280:35760–35766.
30. Infantino S, Moepps B, Thelen M: Expression and regulation of the orphan
receptor RDC1 and its putative ligand in human dendritic and B cells.
J Immunol 2006, 176:2197–2207.
31. Berahovich RD, Zabel BA, Penfold ME, Lewen S, Wang Y, Miao Z, Gan L,
Pereda J, Dias J, Slukvin II, et al: CXCR7 protein is not expressed on human
or mouse leukocytes. J Immunol 2010, 185:5130–5139.
32. Jacobi AM, Reiter K, Mackay M, Aranow C, Hiepe F, Radbruch A, Hansen A,
Burmester GR, Diamond B, Lipsky PE, Dorner T: Activated memory B cell
subsets correlate with disease activity in systemic lupus erythematosus:
delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008,
58:1762–1773.
33. Humpert ML, Tzouros M, Thelen S, Bignon A, Levoye A, Arenzana-Seisdedos
F, Balabanian K, Bachelerie F, Langen H, Thelen M: Complementary
methods provide evidence for the expression of CXCR7 on human B
cells. Proteomics 2012, 12:1938–1948.
34. Juarez-Cedillo T, Zuniga J, Acuna-Alonzo V, Perez-Hernandez N, Rodriguez-
Perez JM, Barquera R, Gallardo GJ, Sanchez-Arenas R, Garcia-Pena Mdel C,
Granados J, Vargas-Alarcon G: Genetic admixture and diversity
estimations in the Mexican Mestizo population from Mexico City using
15 STR polymorphic markers. Forensic Sci Int Genet 2008, 2:e37–e39.
35. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG,
Talal N, Winchester RJ: The 1982 revised criteria for the classification of
systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271–1277.
36. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH: Derivation of
the SLEDAI. a disease activity index for lupus patients. the committee on
prognosis studies in SLE. Arthritis Rheum 1992, 35:630–640.
37. Yee CS, Farewell VT, Isenberg DA, Griffiths B, Teh LS, Bruce IN, Ahmad Y,
Rahman A, Prabu A, Akil M, et al: The use of systemic lupus erythematosus
disease activity index-2000 to define active disease and minimal clinically
meaningful change based on data from a large cohort of systemic lupus
erythematosus patients. Rheumatology (Oxford) 2011, 50:982–988.
38. Nieto JC, Canto E, Zamora C, Ortiz MA, Juarez C, Vidal S: Selective loss of
chemokine receptor expression on leukocytes after cell isolation. PLoS
One 2012, 7:e31297.
39. Balabanian K, Levoye A, Klemm L, Lagane B, Hermine O, Harriague J, Baleux
F, Arenzana-Seisdedos F, Bachelerie F: Leukocyte analysis from WHIM
syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling.
J Clin Invest 2008, 118:1074–1084.
40. Cikos S, Bukovska A, Koppel J: Relative quantification of mRNA:
comparison of methods currently used for real-time PCR data analysis.
BMC Mol Biol 2007, 8:113.
41. Henneken M, Dorner T, Burmester GR, Berek C: Differential expression of
chemokine receptors on peripheral blood B cells from patients with
rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther
2005, 7:R1001–R1013.
42. Payne D, Drinkwater S, Baretto R, Duddridge M, Browning MJ: Expression of
chemokine receptors CXCR4, CXCR5 and CCR7 on B and T lymphocytes
from patients with primary antibody deficiency. Clin Exp Immunol 2009,
156:254–262.
43. Jin Z, Nagakubo D, Shirakawa AK, Nakayama T, Shigeta A, Hieshima K, Yamada
Y, Yoshie O: CXCR7 is inducible by HTLV-1 Tax and promotes growth and
survival of HTLV-1-infected T cells. Int J Cancer 2009, 125:2229–2235.
44. Kumar A, Kremer KN, Dominguez D, Tadi M, Hedin KE: Galpha13 and Rho
mediate endosomal trafficking of CXCR4 into Rab11+ vesicles upon
stromal cell-derived factor-1 stimulation. J Immunol 2011, 186:951–958.
45. Balabanian K, Lagane B, Pablos JL, Laurent L, Planchenault T, Verola O,
Lebbe C, Kerob D, Dupuy A, Hermine O, et al: WHIM syndromes with
different genetic anomalies are accounted for by impaired CXCR4
desensitization to CXCL12. Blood 2005, 105:2449–2457.
46. Cruz-Orengo L, Holman DW, Dorsey D, Zhou L, Zhang P, Wright M,
McCandless EE, Patel JR, Luker GD, Littman DR, et al: CXCR7 influences
leukocyte entry into the CNS parenchyma by controlling abluminal
CXCL12 abundance during autoimmunity. J Exp Med 2011, 208:327–339.
47. Hartmann TN, Grabovsky V, Pasvolsky R, Shulman Z, Buss EC, Spiegel A,
Nagler A, Lapidot T, Thelen M, Alon R: A crosstalk between intracellular
CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation
Biajoux et al. Journal of Translational Medicine 2012, 10:251 Page 16 of 16
http://www.translational-medicine.com/content/10/1/251but not in chemokine-triggered motility of human T lymphocytes and
CD34+ cells. J Leukoc Biol 2008, 84:1130–1140.
48. Rettig MP, Ramirez P, Nervi B, DiPersio JF: CXCR4 and mobilization of
hematopoietic precursors. Methods Enzymol 2009, 460:57–90.
49. Bleul CC, Schultze JL, Springer TA: B lymphocyte chemotaxis regulated in
association with microanatomic localization, differentiation state, and B
cell receptor engagement. J Exp Med 1998, 187:753–762.
50. Wang A, Fairhurst AM, Tus K, Subramanian S, Liu Y, Lin F, Igarashi P, Zhou
XJ, Batteux F, Wong D, et al: CXCR4/CXCL12 hyperexpression plays a
pivotal role in the pathogenesis of lupus. J Immunol 2009, 182:4448–4458.
51. Maecker HT, McCoy JP Jr, Amos M, Elliott J, Gaigalas A, Wang L, Aranda R,
Banchereau J, Boshoff C, Braun J, et al: A model for harmonizing flow
cytometry in clinical trials. Nat Immunol 2010, 11:975–978.
52. Faint JM, Tuncer C, Garg A, Adams DH, Lalor PF: Functional consequences
of human lymphocyte cryopreservation: implications for subsequent
interactions of cells with endothelium. J Immunother 2011, 34:588–596.
53. Costenbader KH, Desai A, Alarcon GS, Hiraki LT, Shaykevich T, Brookhart MA,
Massarotti E, Lu B, Solomon DH, Winkelmayer WC: Trends in the incidence,
demographics, and outcomes of end-stage renal disease due to lupus
nephritis in the US from 1995 to 2006. Arthritis Rheum 2011, 63:1681–1688.
54. Uribe AG, Romero-Diaz J, Apte M, Fernandez M, Burgos PI, Reveille JD,
Sanchez-Guerrero J, Alarcon GS: Impact of immigration on the clinical
expression of systemic lupus erythematosus: a comparative study of
Hispanic patients residing in the USA and Mexico. Rheumatology (Oxford)
2009, 48:1392–1397.
55. Annunziato F, Cosmi L, Galli G, Beltrame C, Romagnani P, Manetti R,
Romagnani S, Maggi E: Assessment of chemokine receptor expression by
human Th1 and Th2 cells in vitro and in vivo. J Leukoc Biol 1999, 65:691–699.
56. Postal M, Appenzeller S: The role of tumor necrosis factor-alpha (TNF-
alpha) in the pathogenesis of systemic lupus erythematosus. Cytokine
2011, 56:537–543.
57. Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont MC, Ranchin B, Fabien
N, Cochat P, Pouteil-Noble C, Trolliet P, et al: Interleukin 17 acts in synergy
with B cell-activating factor to influence B cell biology and the
pathophysiology of systemic lupus erythematosus. Nat Immunol 2009,
10:778–785.
58. Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, Yi J, Guentert T, Tousson A,
Stanus AL, et al: Interleukin 17-producing T helper cells and interleukin
17 orchestrate autoreactive germinal center development in
autoimmune BXD2 mice. Nat Immunol 2008, 9:166–175.
59. Robak E, Kulczycka L, Sysa-Jedrzejowska A, Wierzbowska A, Robak T:
Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in
patients with systemic lupus erythematosus. Eur Cytokine Netw 2007,
18:181–187.
60. Sanchez-Alcaniz JA, Haege S, Mueller W, Pla R, Mackay F, Schulz S, Lopez-
Bendito G, Stumm R, Marin O: Cxcr7 controls neuronal migration by
regulating chemokine responsiveness. Neuron 2011, 69:77–90.
61. Winkelmann R, Sandrock L, Porstner M, Roth E, Mathews M, Hobeika E, Reth
M, Kahn ML, Schuh W, Jack HM: B cell homeostasis and plasma cell
homing controlled by Kruppel-like factor 2. Proc Natl Acad Sci USA 2011,
108:710–715.
62. Sierro F, Biben C, Martinez-Munoz L, Mellado M, Ransohoff RM, Li M, Woehl
B, Leung H, Groom J, Batten M, et al: Disrupted cardiac development but
normal hematopoiesis in mice deficient in the second CXCL12/SDF-1
receptor, CXCR7. Proc Natl Acad Sci USA 2007, 104:14759–14764.
63. Haege S, Einer C, Thiele S, Mueller W, Nietzsche S, Lupp A, Mackay F, Schulz
S, Stumm R: CXC Chemokine receptor 7 (CXCR7) regulates CXCR4 protein
expression and capillary tuft development in mouse kidney. PLoS One
2012, 7:e42814.
64. Odemis V, Boosmann K, Heinen A, Kury P, Engele J: CXCR7 is an active
component of SDF-1 signalling in astrocytes and Schwann cells. J Cell Sci
2010, 123:1081–1088.
doi:10.1186/1479-5876-10-251
Cite this article as: Biajoux et al.: Expression of CXCL12 receptors in B
cells from Mexican Mestizos patients with systemic lupus
erythematosus. Journal of Translational Medicine 2012 10:251.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
